Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
| # | Company | Stage | Amount | Location |
|---|---|---|---|---|
| 151 | Pioneer Square Labs | Series B | $15.0M | Seattle, United States |
| 152 | Semma Therapeutics | Series B | $114.0M | Cambridge, United States |
| 153 | TRELYS | Seed | $80K | San Francisco, United States |
| 154 | Genomics Medicine Ireland | Series A | $40.0M | Dublin, Ireland |
| 155 | Juno Therapeutics | Series B | $134.0M | Seattle, United States |
| 156 | Oncofactor | Series Unknown | $1.0M | Seattle, United States |
Pioneer Square Labs is a studio that creates and launches technology startups.
Semma Therapeutics was founded to develop transformative therapies for Type 1 diabetes patients.
TRELYS is a biotechnology company based in San Francisco, California.
Genomics Medicine Ireland is an Irish life sciences company conducting a study across Ireland of the human genome.
Juno Therapeutics is a clinical-stage company, develops immunotherapies for the treatment of cancer.
Oncofactor develops cancer therapeutics that disrupt signaling pathways between tumors and the immune system.
ARCH Venture Partners has invested in 156 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
ARCH Venture Partners's top investment sectors include Biotechnology, Health Care, Therapeutics, Medical, Life Science. The firm invests across 12 different industry categories.
Among tracked funding rounds, Juno Therapeutics received $134.0M in a Series B round. ARCH Venture Partners's total known invested capital is $14.3B.
ARCH Venture Partners's average investment size is $119.8M across its portfolio of 156 companies.
Discover portfolio companies of other leading venture capital firms and investors.
View All Investors